Raymond James’s $140 target on KYMR

KYMR Kymera Therapeutics Inc

$109 → $140 (+28%) by Oct 2027

Outperform · initiates · said Oct 8, 2026 · 12-month default horizon

Open: judged on the close on Oct 8, 2027

The article this target came from

Raymond James initiates Kymera Therapeutics stock coverage with outperform rating

Investing.com · Oct 8, 2026

set a price target of $140.00

Raymond James’s track record → Kymera Therapeutics Inc →

A fact about what Raymond James published, as reported by Investing.com, not a recommendation from Dalsna Finance; Raymond James is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.